NasdaqGS:OSUR

Stock Analysis Report

Executive Summary

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally.

Snowflake

Fundamentals

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has OraSure Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.9%

OSUR

1.2%

US Medical Equipment

1.0%

US Market


1 Year Return

-45.0%

OSUR

14.9%

US Medical Equipment

8.0%

US Market

Return vs Industry: OSUR underperformed the US Medical Equipment industry which returned 14.9% over the past year.

Return vs Market: OSUR underperformed the US Market which returned 8% over the past year.


Shareholder returns

OSURIndustryMarket
7 Day4.9%1.2%1.0%
30 Day7.1%-2.7%-0.07%
90 Day-4.8%-1.7%-1.0%
1 Year-45.0%-45.0%15.8%14.9%10.4%8.0%
3 Year4.5%4.5%71.4%66.2%46.2%36.7%
5 Year-2.4%-2.4%124.3%99.7%64.3%46.2%

Price Volatility Vs. Market

How volatile is OraSure Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OraSure Technologies undervalued compared to its fair value and its price relative to the market?

0.04%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OSUR ($8.18) is trading below our estimate of fair value ($8.18)

Significantly Below Fair Value: OSUR is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: OSUR is good value based on its PE Ratio (25.7x) compared to the Medical Equipment industry average (42.1x).

PE vs Market: OSUR is poor value based on its PE Ratio (25.7x) compared to the US market (17.6x).


Price to Earnings Growth Ratio

PEG Ratio: OSUR is poor value based on its PEG Ratio (2.4x)


Price to Book Ratio

PB vs Industry: OSUR is good value based on its PB Ratio (1.8x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is OraSure Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

10.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OSUR's forecast earnings growth (10.8% per year) is above the savings rate (2.7%).

Earnings vs Market: OSUR's earnings (10.8% per year) are forecast to grow slower than the US market (14.5% per year).

High Growth Earnings: OSUR's earnings are forecast to grow, but not significantly.

Revenue vs Market: OSUR's revenue (6.9% per year) is forecast to grow slower than the US market (7.2% per year).

High Growth Revenue: OSUR's revenue (6.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OSUR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has OraSure Technologies performed over the past 5 years?

35.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: OSUR's earnings have grown significantly by 35% per year over the past 5 years.

Accelerating Growth: OSUR's earnings growth over the past year (29.5%) is below its 5-year average (35% per year).

Earnings vs Industry: OSUR earnings growth over the past year (29.5%) exceeded the Medical Equipment industry 28.2%.


Return on Equity

High ROE: OSUR's Return on Equity (6.8%) is considered low.


Return on Assets

ROA vs Industry: OSUR's Return on Assets is below or equal to the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: OSUR has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is OraSure Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: OSUR's short term assets ($209.3M) exceeds its short term liabilities ($30.0M)

Long Term Liabilities: OSUR's short term assets (209.3M) exceeds its long term liabilities (9.3M)


Debt to Equity History and Analysis

Debt Level: OSUR is debt free.

Reducing Debt: OSUR has not had any debt for past 5 years.

Debt Coverage: OSUR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: OSUR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: OSUR has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if OSUR's debt is covered by short term assets.


Next Steps

Dividend

What is OraSure Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate OSUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OSUR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if OSUR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OSUR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OSUR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of OraSure Technologies's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average management tenure


CEO

Steve Tang (58yo)

1.5yrs

Tenure

US$2,099,594

Compensation

Dr. Stephen S. Tang, also known as Steve, Ph.D. has been President and Chief Executive Officer at OraSure Technologies, Incorporation since April 01, 2018. Dr. Tang has been Chief Executive Officer and Pre ...


CEO Compensation Analysis

Compensation vs. Market: Steve has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Steve's compensation has increased by more than 20% in the past year.


Management Age and Tenure

2.2yrs

Average Tenure

58yo

Average Age

Experienced Management: OSUR's management team is considered experienced (2.2 years average tenure).


Board Age and Tenure

3.0yrs

Average Tenure

59yo

Average Age

Experienced Board: OSUR's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$8,56014 May 19
Stephen Tang
EntityIndividual
Role
Chief Executive Officer
President
Shares1,000
Max PriceUS$8.56
BuyUS$85,48714 May 19
Jack Jerrett
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares10,000
Max PriceUS$8.55
BuyUS$90,31414 May 19
Roberto Cuca
EntityIndividual
Role
Chief Financial Officer
CFO & Principal Accounting Officer
Shares10,000
Max PriceUS$9.04

Ownership Breakdown


Management Team

  • Steve Tang (58yo)

    President

    • Tenure: 1.5yrs
    • Compensation: US$2.10m
  • Jack Jerrett (60yo)

    Senior VP

    • Tenure: 18.9yrs
    • Compensation: US$973.46k
  • Roberto Cuca (51yo)

    CFO & Principal Accounting Officer

    • Tenure: 1.3yrs
    • Compensation: US$1.05m
  • Brian Smith (60yo)

    Vice Chairman & EVP of Innovation - DNA Genotek

    • Tenure: 2.2yrs
    • Compensation: US$978.65k
  • David Rappaport

    Senior Vice President of Business Development

    • Tenure: 1.5yrs
  • Nancy McLane

    Senior Vice President of Operations

    • Tenure: 0yrs
  • Jeanne Mell

    Vice President of Corporate Communications

    • Tenure: 1.2yrs
  • Tony Zezzo (65yo)

    Executive VP & Business Unit Leader of Infectious Disease

    • Tenure: 2.8yrs
    • Compensation: US$1.06m
  • Kathy Weber (52yo)

    Executive VP & Business Unit Leader of Molecular Solutions

    • Tenure: 6.9yrs
  • Mike Reed (50yo)

    Senior VP of R&D and Chief Science Officer

    • Tenure: 3.5yrs
    • Compensation: US$778.96k

Board Members

  • Chuck Patrick (64yo)

    Independent Director

    • Tenure: 13.8yrs
    • Compensation: US$168.99k
  • Eamonn Hobbs (60yo)

    Independent Director

    • Tenure: 3.6yrs
    • Compensation: US$157.24k
  • Steve Tang (58yo)

    President

    • Tenure: 1.5yrs
    • Compensation: US$2.10m
  • Ronny Lancaster (67yo)

    Independent Director

    • Tenure: 16.4yrs
    • Compensation: US$169.74k
  • Mike Celano (60yo)

    Independent Chairman of the Board

    • Tenure: 1.5yrs
    • Compensation: US$506.36k
  • James Datin (56yo)

    Director

    • Tenure: 0.2yrs
  • Mara Aspinall (57yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$157.24k
  • Aradhana Sarin (44yo)

    Independent Director

    • Tenure: 1.7yrs
    • Compensation: US$562.31k

Company Information

OraSure Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OraSure Technologies, Inc.
  • Ticker: OSUR
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$504.909m
  • Shares outstanding: 61.72m
  • Website: https://www.orasure.com

Number of Employees


Location

  • OraSure Technologies, Inc.
  • 220 East First Street
  • Bethlehem
  • Pennsylvania
  • 18015
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OSURNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1986
EP3DB (Deutsche Boerse AG)YesCommon StockDEEURNov 1986

Biography

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and inter ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 23:40
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.